Yanan Zhu
Stock Analyst at Wells Fargo
(1.89)
# 3,113
Out of 4,944 analysts
74
Total ratings
36.84%
Success rate
-8.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSHA Taysha Gene Therapies | Maintains: Overweight | $7.5 → $8 | $2.91 | +174.91% | 3 | Aug 13, 2025 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $4 → $2.5 | $0.94 | +167.01% | 4 | Aug 13, 2025 | |
| AUTL Autolus Therapeutics | Maintains: Overweight | $6 → $5 | $2.16 | +132.02% | 4 | Aug 13, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $45 → $42 | $14.89 | +182.07% | 8 | Aug 12, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $51 → $38 | $10.90 | +248.62% | 5 | Aug 8, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $18 → $14 | $2.23 | +527.80% | 5 | Aug 8, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $50 → $45 | $10.86 | +314.36% | 5 | Aug 8, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $70 → $75 | $46.23 | +62.23% | 4 | Aug 8, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $48 → $50 | $18.80 | +165.96% | 6 | Aug 7, 2025 | |
| MGX Metagenomi | Maintains: Overweight | $20 → $16 | $1.88 | +751.06% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.5 → $1 | $0.08 | +1,202.08% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $16.86 | +315.18% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $3.39 | +194.99% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $30 | $14.30 | +109.79% | 2 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $4 | $2.29 | +74.67% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $77 | $41.41 | +85.95% | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $40 | $15.92 | +151.26% | 2 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $56.60 | +14.84% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $3.64 | +724.18% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.52 | +672.95% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.45 | +18,267.35% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $637.40 | -48.85% | 1 | Feb 2, 2021 |
Taysha Gene Therapies
Aug 13, 2025
Maintains: Overweight
Price Target: $7.5 → $8
Current: $2.91
Upside: +174.91%
Fate Therapeutics
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $0.94
Upside: +167.01%
Autolus Therapeutics
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $2.16
Upside: +132.02%
Arcturus Therapeutics Holdings
Aug 12, 2025
Maintains: Overweight
Price Target: $45 → $42
Current: $14.89
Upside: +182.07%
RAPT Therapeutics
Aug 8, 2025
Maintains: Overweight
Price Target: $51 → $38
Current: $10.90
Upside: +248.62%
Iovance Biotherapeutics
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $2.23
Upside: +527.80%
Intellia Therapeutics
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $10.86
Upside: +314.36%
Avidity Biosciences
Aug 8, 2025
Maintains: Overweight
Price Target: $70 → $75
Current: $46.23
Upside: +62.23%
Sarepta Therapeutics
Aug 7, 2025
Maintains: Overweight
Price Target: $48 → $50
Current: $18.80
Upside: +165.96%
Metagenomi
May 14, 2025
Maintains: Overweight
Price Target: $20 → $16
Current: $1.88
Upside: +751.06%
May 14, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $1
Current: $0.08
Upside: +1,202.08%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $16.86
Upside: +315.18%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $3.39
Upside: +194.99%
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $35 → $30
Current: $14.30
Upside: +109.79%
Dec 11, 2024
Downgrades: Equal-Weight
Price Target: $7 → $4
Current: $2.29
Upside: +74.67%
Nov 7, 2024
Maintains: Overweight
Price Target: $82 → $77
Current: $41.41
Upside: +85.95%
May 13, 2024
Maintains: Overweight
Price Target: $35 → $40
Current: $15.92
Upside: +151.26%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $56.60
Upside: +14.84%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $3.64
Upside: +724.18%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.52
Upside: +672.95%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $2.45
Upside: +18,267.35%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $637.40
Upside: -48.85%